Plain-English translation of NCT07416890 on ClinicalTrials.gov ↗ ·
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of three medications—thiotepa, pirtobrutinib, and sintilimab—to treat a type of cancer that starts in the brain called central nervous system lymphoma. The trial is designed for people whose lymphoma has returned after previous treatment or who are too frail to receive the standard chemotherapy that is usually used. The study will measure how well this medication combination works and how safe it is.
Brain lymphoma is a serious cancer that is difficult to treat, especially in older patients or those who are very ill and cannot tolerate standard chemotherapy. This trial exists to find a gentler but still effective treatment option for these vulnerable patients whose lymphoma has either returned or who could not receive traditional treatment.
You likely qualify if…
You likely don't qualify if…
You will receive the three-medication combination in cycles lasting 21 days, with a maximum of 6 treatment cycles over about 4–5 months. During induction treatment, you'll have regular clinic visits for blood tests, imaging scans of your brain, and spinal fluid tests to check how the cancer is responding. Depending on your response, you may then receive additional treatment (either a stem cell transplant or radiation therapy) or continue with maintenance therapy using two of the medications for up to one year. After treatment ends, you'll have follow-up visits at regular intervals to monitor your health and watch for any signs of the cancer returning.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
China